Video

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Barocas led a study in which investigators followed men with prostate cancer from diagnosis on. Patients were given self-reported questionnaires regarding adverse events (AEs). Taken collectively, investigators concluded that each treatment has a unique AE profile. For example, erectile dysfunction and urinary leakage are more likely to result from surgery. Erectile dysfunction is also a concern with radiation. Though, it appears to be a gradual decline with radiation compared with surgery, says Barocas.

At 5 years, many of the resulting AEs taper off, adds Barocas. Though, the risk of urinary incontinence is still higher in patients who undergo surgery versus those who don’t.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center